drugset / Trial / NCT03927248
PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of the pilot study is to determine activity of PAC-1 and nivolumab combination in subjects with metastatic renal cell carcinoma previously treated with immune checkpoint inhibitor therapy as assessed by objective response rate (ORR) using RECIST 1.1 criteria.
Timeline
- Start
- 2020-09
- Primary completion
- 2021-09
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
| Subject | PAC-1 | Small molecule | 750 mg | Oral |